Building on our global leadership in meningococcal vaccination and our longstanding ... 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q4 Results for 2024.

Two long-planned vaccine meetings — one at the US Centers for Disease Control and another at the US Food and Drug ...

Meningococcal disease epidemiology also ... These data, combined with the mortality and morbidity rates, should form the basis for vaccine recommendations. Vaccine recommendations will depend ...

Dr Rehana Kausar Vaccination is one of the most visible success stories of public health. The eradication of smallpox, the ...

He added that IMD leads to death in a matter of hours due to its rapid course of progression, including an average incubation ...

The school division is partnering with the Virginia Department of Health’s Richmond and Henrico Health Districts to offer a free vaccine clinic ...

The vaccine combines antigenic components of the meningococcal group B vaccine (Bexsero ... The benefit is protection from 5 different forms (serotypes) of Neisseria meningitidis, commonly called ...

Building on our global leadership in meningococcal vaccination and our longstanding commitment to ... those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and ...

An application form (HC1) for help with NHS charges is available ... you should arrange a free catch up vaccination as soon as possible. MenACWY vaccine: This vaccine protects against meningococcal ...

The US FDA has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease.

For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after stopping rituximab.

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).